Fulcrum Therapeutics earnings were -$85.0M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest FULC earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$26.2M, up 38.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, FULC reported annual earnings of -$74.9M, with 670% growth. The next FULC earnings date is Aug 4, 2026.
Fulcrum Therapeutics Earnings Reports & History FAQ
What were Fulcrum Therapeutics's earnings last quarter?
On FULC's earnings call on Aug 4, 2026, Fulcrum Therapeutics (NASDAQ: FULC) reported Q2 2026 earnings per share (EPS) of -$0.34, up 21.43% year over year. Total FULC earnings for the quarter were -$26.18 million. In the same quarter last year, Fulcrum Therapeutics's earnings per share (EPS) was -$0.28.
The next FULC earnings date is Aug 4, 2026. Add FULC to your watchlist to be reminded of Fulcrum Therapeutics's next earnings date.
Is Fulcrum Therapeutics profitable or losing money?
As of the last Fulcrum Therapeutics earnings report, Fulcrum Therapeutics is currently losing money. Fulcrum Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$85.00 million, a 16.1% increase year over year.
What was FULC's earnings growth in the past year?
As of Fulcrum Therapeutics's earnings date in Aug 4, 2026, Fulcrum Therapeutics's earnings has grown year over year. FULC earnings in the past year totalled -$85.00 million.
What are Fulcrum Therapeutics's earnings expectations?
The current EPS estimate for Fulcrum Therapeutics's earnings report in Aug 4, 2026 is -$0.21.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.